EB-SELECT Single-Target CAR-NK Cells

Cell therapy

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Solid Tumors

Competitive landscape

This drug's own stage for Solid Tumors: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
EB-SELECT Single-Target CAR-NK Cells: this drugPhase 1/2Cell therapyPersonalized, biomarker-guided allogeneic chimeric antigen receptornot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)Weak signalNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETnot yet gradedNo reviewed efficacy summary in this indication
ALG.APV-527Phase 1/2Multispecific antibody4-1BB (CD137) x 5T4not yet gradedNo reviewed efficacy summary in this indication
CR-001
Phase 1/2(overall)
Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
EB-SELECT Dual-Target CAR-NK CellsPhase 1/2Cell therapyTumor antigen menu (TROP2, MSLN, B7-H3, HER2)not yet gradedNo reviewed efficacy summary in this indication
Micvotabart PelidotinPhase 1/2Antibody–drug conjugateED-B domain of fibronectinnot yet gradedNo reviewed efficacy summary in this indication
Linebacker
—(overall)
Small moleculePIM kinases (PIM1/2/3)not yet gradedNo reviewed efficacy summary in this indication
RP3DiscontinuedOncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow EB-SELECT Single-Target CAR-NK Cells to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2027-12-28 · NCT07410494 · CT.gov ↗
What to watch

See the full readout calendar ↗